Publications by authors named "B L Rapoport"
Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with previous standard dosing of 200 mg or 2 mg/kg every 3 weeks, and early results of cohort B of the phase 1 KEYNOTE-555 study. Results after ≥1 year of potential follow-up for all patients in cohort B of KEYNOTE-555 are presented. Patients aged ≥18 years with previously untreated stage III/IV melanoma received pembrolizumab 400 mg every 6 weeks for ≤18 cycles.
View Article and Find Full Text PDFArticle Synopsis
- Endovascular embolization is used as a supportive treatment for meningioma surgery, but evaluating its effectiveness is complicated because MRI scans are done before embolization and after the tumor is removed.
- Researchers conducted a study using preoperative MRI after embolization to better measure how effective the procedure was, grading the extent of tumor devascularization and analyzing differences based on tumor location and blood supply.
- The study found that the degree of devascularization correlated well with the volumetric extent of embolization, providing a clearer and more quantifiable way to assess the effectiveness of embolization before surgery.
Article Synopsis
- Preoperative embolization is an endovascular procedure that helps in the surgical removal of meningiomas but lacks a standardized system to measure its effectiveness during the procedure.
- Researchers developed an angiographic grading system to help assess and report the level of tumor devascularization achieved through this process, involving a scale from 0 (no embolization) to 4 (complete embolization).
- Analysis of data from 80 patients revealed that tumor location and the type of arterial feeders significantly influenced the success of embolization, with certain tumor types showing higher devascularization grades and a low complication rate of 2.5%.*
Purpose: Quality of life (QoL), appetite, cachexia, and biomarkers [albumin, hemoglobin (Hb), neutrophils, lymphocytes, platelets, C-reactive protein (CRP), tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), interleukin 8 (IL-8), C-X-C motif chemokine ligand 5 (CXCL5) and citrullinated histoneH3 (H3Cit)] were compared for 40 cases with advanced cancer and 40 healthy controls. Baseline differences and significant relationships were explored for biomarkers with QoL, appetite, and cachexia.
Methods: In a prospective case-control, age and sex matched study, the European Organisation for the Research and Treatment of Cancer Quality of Life-C30 questionnaire (EORTC-QLQ-C30) for QoL, the Functional Assessment of Anorexia and Cachexia Therapy assessment (FAACT A/CS-12) for appetite, and a five-factor cachexia assessment tool for cachexia assessment were performed.